MedTrace Logo

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

NCT07672561 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2026-06-29

No results posted yet for this study

Summary

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Conditions

Interventions

DRUG

Drug:WD-890

WD-890 tablet will be administered orally.

DRUG

Drug: placebo

Placebo tablet will be administered orally.

Sponsors & Collaborators

  • Zhejiang Wenda Pharma Technology LTD.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-18
Primary Completion
2026-11-30
Completion
2027-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07672561 on ClinicalTrials.gov